Neuroregeneration Therapies For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Neuroregeneration therapies represent a transformative approach to treating neurodegenerative diseases by focusing on repairing, replacing, or regenerating damaged neurons and neural circuits. Unlike disease-modifying therapies that primarily target underlying pathology (such as amyloid-beta plaques or tau tangles), neuroregenerative approaches aim to restore lost neuronal function, rebuild neural networks, and promote recovery of cognitive and motor abilities.
This field encompasses multiple therapeutic strategies including cell replacement therapy, neurotrophic factor delivery, axonal regeneration promotion, and stimulation of endogenous neural stem cells.
| Neuroregeneration Therapies | |
|---|---|
| Primary Goal | Restore neuronal function and connectivity |
| Key Approaches | Cell therapy, neurotrophic factors, axonal regeneration, endogenous repair |
| Target Diseases | [Parkinson's Disease](/diseases/parkinsons-disease), [Alzheimer's Disease](/diseases/alzheimers-disease), [Huntington's Disease](/diseases/huntingtons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis-als) |
| Clinical Status | Multiple Phase 1/2 trials, some Phase 3 |
| Leading Modalities | iPSC-derived neurons, GDNF delivery, anti-Nogo therapy |
The adult brain contains neural stem cells in two primary regions [1]:
Therapeutic strategies to enhance endogenous neurogenesis:
| Approach | Mechanism | Status |
|---|---|---|
| Exercise/Enrichment | Increases BDNF, hippocampal neurogenesis | Clinical |
| Growth factors | FGF2, EGF stimulate NSC proliferation | Preclinical |
| Small molecules | P7C3, PDE inhibitors enhance neurogenesis | Clinical trials |
| Modulators | Wnt agonists, Notch inhibitors | Research |
Challenges: Neurogenesis declines with age and is impaired in neurodegenerative diseases. Strategies must overcome this deficit while ensuring proper integration of new neurons.
Unlike the peripheral nervous system, CNS axons have limited regenerative capacity due to [2]:
Intrinsic limitations:
Extrinsic inhibitors:
Therapeutic targets:
| Target | Approach | Status |
|---|---|---|
| Nogo-A/NgR1 | Anti-Nogo antibodies, NgR1 decoys | Phase 2/3 (stroke, SCI) |
| RhoA/ROCK | Small molecule inhibitors | Clinical trials |
| PTEN deletion | Gene therapy to enhance growth | Preclinical |
| cAMP elevation | PDE4 inhibitors, forskolin | Clinical |
| KLF4/9 suppression | Transcriptional reprogramming | Research |
Restoring synaptic function is crucial for cognitive recovery [3]:
Approaches:
Transplanting new neurons or progenitors to replace lost cells [4]:
PD is the leading target for cell replacement therapy due to well-defined cell loss [5]:
Leading programs:
| Program | Source | Trial Phase | Key Features |
|---|---|---|---|
| CiRA (Kyoto) | Autologous iPSC | Phase 1/2 | First patient transplanted 2018 |
| BlueRock/Bayer | Allogeneic iPSC | Phase 1 | "Off-the-shelf" approach |
| Aspen Neuroscience | Autologous iPSC | Phase 1/2 | Patient-specific cells |
| Memory-GSK | Allogeneic iPSC | Phase 1 | Immunomodulation |
Manufacturing considerations:
Converting astrocytes to dopamine neurons in situ [6]:
HD involves selective loss of striatal medium spiny neurons (MSNs) [7]:
Approaches:
Challenges:
ALS involves progressive motor neuron loss [8]:
Challenges unique to ALS:
Current approaches:
| Factor | Primary Target | Disease Application | Delivery Challenge |
|---|---|---|---|
| GDNF | Dopamine neurons | PD | Requires intraparenchymal infusion |
| BDNF | Cortical/hippocampal | AD, HD | Poor BBB penetration |
| NGF | Cholinergic neurons | AD | Painful side effects |
| CNTF | Motor neurons | ALS | Weight loss, toxicity |
| NT-3 | Proprioceptive neurons | SCI | Diffuse expression needed |
GDNF supports survival and function of dopaminergic neurons [9]:
Delivery approaches:
Direct infusion: Convection-enhanced delivery (CED) to putamen
Encapsulated cell therapy: Immunoisolated cells producing GDNF
AAV-GDNF gene therapy: Viral delivery for sustained expression
GDNF mimetics: Small molecules activating Ret receptor
BDNF supports hippocampal and cortical neurons [10]:
Clinical challenges:
Alternative approaches:
NGF supports basal forebrain cholinergic neurons [11]:
AAV-NGF (CERE-110):
Nogo-A is a major myelin-associated inhibitor of axonal regeneration [12]:
The RhoA-ROCK pathway mediates growth inhibition signals [13]:
| Agent | Type | Status |
|---|---|---|
| Fasudil | ROCK inhibitor | Approved in Japan for stroke |
| Y-27632 | ROCK inhibitor | Preclinical |
| C3 transferase | RhoA inhibitor | Preclinical |
| Veritide | RhoA antagonist | Research |
PTEN is a negative regulator of mTOR that limits axonal regeneration [14]:
| Trial | Modality | Disease | Phase | Agent |
|---|---|---|---|---|
| TRANSEURO | Fetal dopamine cells | PD | Phase 2 | Fetal VM tissue |
| Kyoto iPSC | Autologous iPSC | PD | Phase 1/2 | iPS-dopamine |
| BlueRock | Allogeneic iPSC | PD | Phase 1 | Bemdaneprocel |
| STEMS-PD | MSC infusion | PD | Phase 2 | MSC |
| ASTRO | AAV-GDNF | PD | Phase 1 | AAV2-GDNF |
| Nogo-A Stroke | Anti-Nogo | Stroke | Phase 2 | ATI-355 |
| Challenge | Description | Potential Solutions |
|---|---|---|
| Integration | New neurons must form correct connections | Activity-based training, guidance cues |
| Survival | Hostile disease environment | Anti-inflammatory co-therapies |
| Scalability | Manufacturing clinical-grade cells | Automated bioreactors, standardized protocols |
| Timing | When to intervene | Biomarker-guided treatment |
| Rejection | Immune response to allogeneic cells | HLA-matching, immunosuppression |
| Aspect | Key Points |
|---|---|
| Goal | Restore neuronal function and connectivity |
| Cell therapy | iPSC-derived neurons for PD, HD, ALS |
| Neurotrophic factors | GDNF, BDNF, NGF delivery via gene therapy or infusion |
| Axonal regeneration | Anti-Nogo, ROCK inhibitors, PTEN deletion |
| Leading indication | Parkinson's Disease (dopamine neuron replacement) |
| Clinical status | Multiple Phase 1/2 trials; Phase 3 in stroke/SCI |
| Key challenge | Circuit integration and functional recovery |
The study of Neuroregeneration Therapies For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Ming GL, Song H. Adult neurogenesis in the mammalian brain: significant answers and significant questions. Neuron. 2011;70(4):687-702. DOI:10.1016/j.neuron.2011.05.001 ↩︎
Schwab ME, Strittmatter SM. Nogo limits neural plasticity and recovery from CNS injury. Curr Opin Neurobiol. 2014;27:85-91. DOI:10.1016/j.conb.2014.03.007 ↩︎
Poo MM, et al. What is synaptic plasticity? Nat Rev Neurosci. 2016;17(9):593. DOI:10.1038/nrn.2016.100 ↩︎
Parmar M, et al. How can hPSCs replace dopaminergic neurons in Parkinson's patients? Cell Stem Cell. 2020;26(1):1-3. DOI:10.1016/j.stem.2019.12.003 ↩︎
Kriks S, et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature. 2011;480(7378):547-551. DOI:10.1038/nature10648 ↩︎
Rivetti di Val Cervo P, et al. Induction of functional dopamine neurons from human astrocytes in vitro and in vivo. Nat Biotechnol. 2017;35(5):444-452. DOI:10.1038/nbt.3835 ↩︎
Rossignol J, et al. Mesenchymal stem cell transplantation for Huntington's disease. Cell Transplant. 2015;24(4):629-644. DOI:10.3727/096368915X687640 ↩︎
Thomsen GM, et al. Stem cell transplantation for ALS. Neurotherapeutics. 2014;11(3):535-548. DOI:10.1007/s13311-014-0286-7 ↩︎
Barker RA, et al. GDNF and the treatment of Parkinson's disease. Nat Rev Neurol. 2020;16(4):221-232. DOI:10.1038/s41582-020-0334-2 ↩︎
Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov. 2011;10(3):209-219. DOI:10.1038/nrd3366 ↩︎
Tuszynski MH, et al. Nerve growth factor gene therapy: activation of neuronal responses in Alzheimer's disease. JAMA Neurol. 2015;72(10):1139-1147. DOI:10.1001/jamaneurol.2015.1807 ↩︎
Lee JK, et al. Nogo receptor antagonism promotes stroke recovery by enhancing synaptic plasticity. J Neurosci. 2015;35(11):4769-4781. DOI:10.1523/JNEUROSCI.3014-14.2015 ↩︎
Fournier AE, et al. Inhibition of Rho promotes axonal regeneration. J Neurosci. 2003;23(4):1416-1423. DOI:10.1523/JNEUROSCI.23-04-01416.2003 ↩︎
Park KK, et al. PTEN deletion enhances the regenerative ability of adult corticospinal neurons. Nature. 2008;452(7186):639-642. DOI:10.1038/nature06857 ↩︎